Aurinia Pharmaceuticals News

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) Have Lost 64%, as Stock Drops 9.5% This Past Week

Yahoo FinanceMay 26 08:53

Retail Investors Who Hold 54% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Gained 7.5%, Institutions Profited as Well

Key Insights Significant control over Aurinia Pharmaceuticals by retail investors implies that the general public has more power to influence management and governance-related decisions The top 25 s

Simply Wall StMay 22 11:20

Analysis Showing LUPKYNIS Is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024

An updated analysis showed that LUPKYNIS is a cost-effective treatment for lupus nephritis, on par with other interventions for diabetes, blood pressure, and hyperlipidemia in adult patients with active lupus nephritis

BusinesswireMay 14 05:00

Aurinia Reports Presentation Of Two Studies At The Annual Congress Of Clinical Rheumatology

The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), in combination with MMF and steroids, for the treatment

BenzingaMay 9 05:12

Aurinia Presents Data Reinforcing LUPKYNIS Safety and Efficacy for People With Lupus Nephritis at Congress of Clinical Rheumatology East 2024

A propensity analysis of ALMS, AURA-LV, and AURORA 1 suggested that initial therapy with LUPKYNIS plus standard of care reduced exposure to potential toxicities and demonstrated earlier reductions in proteinuria when

BusinesswireMay 9 05:00

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference May 7, 2024 • 6:00 am EDT Download as PDF ROCKVILLE, Md. & EDMONTON, Alberta--(

Aurinia PharmaceuticalsMay 7 05:00

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 3 12:02

RBC Capital Gives a Buy Rating to Aurinia Pharmaceuticals (AUPH)

TipRanksMay 3 05:41

Aurinia Pharmaceuticals' LUPKYNIS: A Strong Buy on Surging Sales and Positive Market Indicators

TipRanksMay 3 05:36

Earnings Call Summary | Aurinia Pharmaceuticals(AUPH.US) Q1 2024 Earnings Conference

The following is a summary of the Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call Transcript:Financial Performance:Aurinia reported Q1 net revenue of $50.3 million, marking a 46% YoY growth.

Futu NewsMay 2 13:48 · Conference Call

Aurinia Pharmaceuticals Sees Robust Growth in 2024

TipRanksMay 2 05:38

Aurinia Pharmaceuticals (AUPH.US): The 2024 Q1 financial report achieved revenue of $50.303 million, previous value of US$344.09 million, expected value of US$47.45 million; earnings per share were -0.07 USD, previous value of -0.18 USD, and expected valu

Aurinia Pharmaceuticals (AUPH.US): The 2024 Q1 financial report achieved revenue of $50.303 million, previous value of US$344.09 million, expected value of US$47.45 million; earnings per share were -0.07 USD, previous value of -0.18 USD, and expected value of -0.14 USD.

Zhitong FinanceMay 2 05:31

Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, Vs. Street Est of $47.1M

06:12 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, vs. Street Est of $47.1M

MT NewswiresMay 2 05:12

Aurinia Pharmaceuticals Maintains Established Net Pdt Rev Guidance for a Range of $200M to $220M >AUPH

Aurinia Pharmaceuticals Maintains Established Net Pdt Rev Guidance for a Range of $200M to $220M >AUPH

Dow JonesMay 2 05:04

Aurinia Pharmaceuticals 1Q Loss/Shr 7c >AUPH

Aurinia Pharmaceuticals 1Q Loss/Shr 7c >AUPH

Dow JonesMay 2 05:04

Aurinia Reiterates 2024 Net Product Revenue Guidance Of $200M-$220M

Aurinia Reiterates 2024 Net Product Revenue Guidance Of $200M-$220M

BenzingaMay 2 05:03

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results

Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and e

BusinesswireMay 2 05:00

Press Release: Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results -- Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first qu

Dow JonesMay 2 05:00

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Aurinia Pharmaceuticals (AUPH) and 908 Devices (MASS)

TipRanksMay 2 01:22

Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)

TipRanksMay 2 01:20